Acrobiosystems Co

Acrobiosystems Co Total Assets

The Total Assets of Acrobiosystems Co (301080.SZ) as of Nov 16, 2026 is 3.01 B CNY. In the previous year, Total Assets was 2.91 B CNY — a change of 3.26% (higher).

Total Assets

3.01 BCNY

YoY

3.26%

Last updated:

Total Assets of Acrobiosystems Co is 2025 3.01 B CNY. Total Assets of Acrobiosystems Co was 2024 2.91 B CNY. It decreases by 3.26% higher compared to the previous year.

The Acrobiosystems Co Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
83.47 M CNY
Jan 1, 2019
113.46 M CNY
Jan 1, 2020
241.34 M CNY
Jan 1, 2021
2.54 B CNY
Jan 1, 2022
2.74 B CNY
Jan 1, 2023
2.81 B CNY
Jan 1, 2024
2.91 B CNY
Jan 1, 2025
3.01 B CNY
The Acrobiosystems Co Total Assets history
YEARTotal AssetsYoY
3.01 BCNY+3.26%
2.91 BCNY+3.59%
2.81 BCNY+2.83%
2.74 BCNY+7.51%
2.54 BCNY+954.44%
241.34 MCNY+112.71%
113.46 MCNY+35.93%
83.47 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Total Assets of Acrobiosystems Co is 3.01 B CNY in 2025.

Total Assets of Acrobiosystems Co changed from 2.91 B CNY to 3.01 B CNY, representing a 3.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Acrobiosystems Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co